Ovarian Cancer Midwest Focus Conference
November 10-11, 2022
Hybrid Conference: Virtual & In-Person | Graduate Hotel - Minneapolis, MN
ABOUT OUR CONFERENCE
The 2022 Ovarian Cancer Midwest Focus (OCMF) Conference will be both an in-person and a virtual conference that will include live streamed discussion rounds with national and international speakers, short talks based on abstracts, and group discussions. Topics will include Early Detection, Immunotherapy, Novel Therapeutics, Metabolism, Preclinical Models of Ovarian Cancer, Personalized Medicine, Microenvironment, Epigenetics, PARP Inhibitors, Chemoresistance, Combination Therapy, Clinical Studies, Technology Commercialization, and Career Development (lunch and learn).
Martina Bazzaro, PhD - University of Minnesota - Twin Cities Campus
Ronny Drapkin, MD, PhD - University of Pennsylvania - Perelman School of Medicine
Melissa Geller, MD, MS - University of Minnesota - Twin Cities Campus
Andrew Godwin, PhD - University of Kansas - Kansas City
Gottfried E. Konecny, MD - University of California - Los Angeles
Boris Winterhoff, MD - University of Minnesota - Twin Cities Campus
Virtual Attendee Information
We will be using the "Zoom Webinar" platform.
Conference/Zoom Link for both days:
Location, Accommodations and Parking Information
The Graduate Hotel
How to use your booking link:
- Select the exact dates of your stay (top of page)
- Click on check availability
- Select room type – “Book now”
- Confirm your stay, enter your name & credit card
A list of our past distinguished speakers
Maria Barbolina, PhD, from the University of Illinois Cancer Center, presenting on Microtubules (MTs) and their Dynamics in Chemo-Resistant Ovarian Cancer.
Ron Buckanovich, MD, PhD, from the Magee-Womens Research Institute, presenting on Ovarian Cancer Models: A Humanized Model of Ovarian Cancer.
Uri Ben-David, PhD, from the Tel Aviv University, presenting on Aneuploidy in Cancer and in Chemoresistance.
Andrew K Godwin, PhD, from the University of Kansas Cancer Center, presenting on Exosomes as Diagnostic and Early Detection Tools.
Panagiotis A. Konstantinopoulos, MD, PhD, from the Harvard Medical School, presenting on Novel Agent Combinations: Targeting Synergism and Potentiation.
Keren Levanon, MD, PhD, from the Chaim Sheba Medical Center, presenting on Lavage Proteomics.
Stéphanie Lheureux, MD, PhD, from the Princess Margaret Cancer Centre, presenting on Novel Agent Combinations: Targeting Adaptive and Resistance Response.
Karen H. Lu, MD, from the MD Anderson Cancer Center, presenting on Risk-Reducing Salpingectomy (WISP, TUBA, NRG).
Kirk J. McManus, MSc, PhD, from the University of Manitoba, presenting on Dynamics of Chromosome Instability.
Sohrab P. Shah, PhD, from the Memorial Sloan Kettering Cancer Center, presenting on Malignant and Immunologic Clonal Dynamic.
Jason Sheltzer, PhD, from the Cold Spring Harbor Laboratory, presenting on Aneuploidy in Cancer.
Ie-Ming Shih, MD, PhD, from the Johns Hopkins University School of Medicine, presenting on Tubal Origins.
Fiona Simpkins, MD, from the University of Pennsylvania, presenting on Overcoming PARPi Resistance.
Victor Velculescu, MD, PhD, from the John Hopkins Medicine, presenting on Emerging Liquid Bx Technology.
Beth Weaver. PhD, from the University of Wisconsin – Madison, presenting on CIN, p53 and Chemoresistance in Solid Tumors.
Weiping Zou, MD, PhD, from the University of Michigan, presenting on Dynamic Heterogeneity of Immune Cells in Ovarian Cancer.